Program Chair
Stella E. Lee, MD
Section Chief, Rhinology
Division of Otolaryngology—Head and Neck Surgery
Department of Surgery
Massachusetts General Hospital
Brigham and Women’s Hospital
Harvard Medical School
Boston, MA
PROGRAM OVERVIEW
This enduring activity will help healthcare professionals identify evidence-based strategies to manage Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), understand the clinical evidence for novel, emerging therapies for CRSwNP, and choose the most appropriate treatment based on individual patient characteristics.
TARGET AUDIENCE
This activity is designed to meet the educational needs of otolaryngologists, allergists, primary care physicians, nurses, nurse practitioners, pharmacists, and other members of the multidisciplinary team that care for patients with CRSwNP.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Identify strategies to manage CRSwNP that are aligned with evidence-based guidelines
- Discuss the clinical evidence for novel, emerging therapeutic agents for the treatment of CRSwNP
- Describe strategies to effectively select treatment based on patient-specific factors and expert guidance
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NURSES (ANCC) CREDIT DESIGNATION
Amedco LLC designates this activity for a maximum of 1.0 ANCC contact hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIP(S)
| Faculty Member | Disclosures |
| Dr. Buchheit | Consultant for AstraZeneca, Sanofi, Genentech, Regeneron Pharmaceuticals, Inc., and GlaxoSmithKline. Receives royalties from UpToDate. |
| Dr. Damask | Advisory board for GlaxoSmithKline, Sanofi and Regeneron Pharmaceuticals, Inc. Speakers bureau for GlaxoSmithKline, OptiNose, Sanofi, and Regeneron Pharmaceuticals, Inc. Conducted Clinical research for AstraZeneca, GlaxoSmithKline, OptiNose, Sanofi, Regeneron Pharmaceuticals, Inc. |
| Dr. Lee | Consultant for and received clinical trial funding from AstraZeneca, GlaxoSmithKline, Genentech, Lyra Therapeutics, OptiNose and Sanofi, Regeneron Pharmaceuticals, Inc. |
| Dr. Peters | Consultant for AstraZeneca, GlaxoSmithKline, Merck, OptiNose, Regeneron Pharmaceuticals, Inc., and Sanofi; conducts research for AstraZeneca, Merck, Regeneron Pharmaceuticals, Inc. and Sanofi; and receives royalties from UpToDate. |
| Dr. Stevens | Consultant for Regeneron Pharmaceuticals, Inc., GlaxoSmithKline, and Melinta Therapeutics |
All relevant financial relationships have been mitigated.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Debra Gordon, MS, Medical Director for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Russie Allen, Accreditation and Outcomes Manager for Med Learning Group, has nothing to disclose.
- Felecia Beachum, Sr. Program Manager for Med Learning Group, has nothing to disclose.
- Naomi De Brito, Associate Program Manager for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity.
In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation.
Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected]
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at https://medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: November 29, 2023
EXPIRATION DATE: November 29, 2024
Copyright © 2023 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
